The beaten down stock in question is Oneview Healthcare (ASX: ONE).

In early afternoon trade on Wednesday, OneView Healthcare shares are down 3.0%, trading for 16 cents apiece.

This sees the ASX All Ords healthcare share down a painful 60.0% year to date.

Looking ahead, however, Securities Vault's Nathan Lodge believes the company, which provides digital tools for patients, families and caregivers, could be poised to rebound (courtesy of The Bull).

OneView is currently partnered with healthcare systems in the United States, Australia, Ireland, the Middle East and Asia, helping to unify the care experience in more than 80 hospitals.

Should you buy the ASX All Ords healthcare share today?

"Its care experience platform integrates patient engagement tools into hospital systems," said Lodge, who has a buy recommendation on the ASX All Ords healthcare share.

"The company's offering should generate demand," he added. "Potential upside exits following positive momentum."

According to Lodge:

The investment thesis hinges on hospital digitisation and patient experience mandates, particularly in the US, where funding tailwinds remain supportive.

As for the second reason you might want to buy OneView shares today, Lodge said, "As deployments scale up, Oneview's recurring revenue model should drive operating leverage."

Summing up his bullish outlook on the beaten down stock, Lodge concluded, "Importantly, the company has already secured major hospital clients, reducing execution risk compared to earlier stage peers."

What's the latest from OneView?

OneView Healthcare reported its March quarter results on 27 April.

The ASX All Ords healthcare share closed up 2.9% on the day after reporting a $9 million quarter-on-quarter increase in its cash balance to $17.1 million. That was spurred by a successful $19 million capital raising during the quarter.

"The successful completion of the recent capital raise in extremely challenging market conditions represents a strong endorsement of Oneview's strategy and execution," OneView Healthcare CEO James Fitter said.

Looking ahead, Fitter added:

The first quarter of the year has been a busy period for the business, with continued engagement across our sales channels and progress that supports our objectives for 2026…

With a strengthened balance sheet, continued deployment activity across new and existing customers, and growing demand for digitally supported bedside experiences, the company is well positioned to maintain momentum as we progress through the year.

The post 3 reasons this beaten down ASX All Ords healthcare share could come roaring back appeared first on The Motley Fool Australia.

It has just given its verdict on several small-cap ASX shares. Here's what it is recommending:

Mach7 Technologies Ltd (ASX: M7T)

Securities Vault has named Mach7 as a small-cap ASX share to buy.

It believes the enterprise imaging platform provider is well-placed to grow its recurring revenue thanks to expanding budgets in the US healthcare sector. It explains:

The company provides enterprise imaging platforms used by hospitals across the globe, positioning it as a scalable SaaS (software-as-a-service) style health technology play. Recent quarterly updates have shown improving cost discipline and operating leverage. The real upside lies in recurring revenue growth and contract wins across North America, where healthcare information technology budgets are structurally expanding.

As hospitals modernise legacy systems, Mach7's vendor-neutral archive (VNA) offering becomes increasingly relevant. If management continues to convert its pipeline into contracts, the market could materially re-rate earnings visibility. At current levels, it still trades at a discount to global peers despite similar growth characteristics.

Oneview Healthcare (ASX: ONE)

Another small-cap ASX share that Securities Vault rates as a buy is Oneview Healthcare.

It is feeling positive about the care experience platform provider's outlook due to favourable funding tailwinds in the US market. It explains:

Its care experience platform integrates patient engagement tools into hospital systems. The company's offering should generate demand. Potential upside exits following positive momentum. The investment thesis hinges on hospital digitisation and patient experience mandates, particularly in the US, where funding tailwinds remain supportive.

As deployments scale up, Oneview's recurring revenue model should drive operating leverage. Importantly, the company has already secured major hospital clients, reducing execution risk compared to earlier stage peers.

WRKR Ltd (ASX: WRK)

One small-cap ASX share that Securities Vault isn't positive on is WRKR. It has named the workforce compliance and payroll solutions company's shares as a sell this week.

Securities Vault has concerns over elevated execution risks and an uncertain pathway to profitability. It explains:

The company operates in workforce compliance and payroll solutions—an attractive theme—but execution risk remains elevated, in our view. Despite operating in a growing sector, the pathway to profitability remains uncertain. The company posted a loss after tax of $2.66 million in the first half of 2026. Investors chasing the theme may be better served in bigger, more established platforms offering stronger execution capabilities.

The post Buy, hold, sell: 3 small cap ASX shares appeared first on The Motley Fool Australia.

This largely focuses on quality, blue-chip companies and diversified ASX ETFs.

However, there is no denying that ASX small-caps can be a profitable allocation in any portfolio. 

So if you are looking to sprinkle an allocation into ASX small-caps with upside potential, these three have drawn positive attention from brokers following their recent results.

Oneview Healthcare PLC (ASX: ONE)

Oneview Healthcare provides interactive patient care

The company's Care Experience Platform (CXP) is a unified set of digital tools in a single bedside solution that connects patients, families and care teams with services, education, and information during hospital stays.

A recent report from Bell Potter has indicated ASX small-cap could double in value over the next year. 

The company recently released a quarterly report.

Following this, Bell POtter retained its speculative buy recommendation and price target of 45 cents. 

From yesterday's closing price of 17.5 cents, this indicates a potential upside of 157%. 

Bell Potter did note that while the company expects ~20% growth in live endpoints driven by a strong pipeline, execution risk remains as investors await faster conversion and stronger revenue growth, with valuation unchanged and caution maintained until consistent financial performance is demonstrated.

Despite improving thematics and the need for hospitals to utilise efficiency tools to plug the operating impact of nurse shortages, we remain cautious ahead of more consistent performance on conversion and financial performance.

WRKR Ltd (ASX: WRK)

WRKR is a financial technology company, which engages in the design of innovative overlay capability for banking, wealth management, pensions, and financial services.

It also recently released a quarterly report.

Following the release, Bell Potter reaffirmed buy recommendation, however reduced its share price target to 17.5 cents.

This target is a healthy 57% higher than yesterday's closing price. 

The broker noted it was impressed with a reported record cash receipts of $4.3m, including payment of $0.9m outstanding invoices and $0.7m PaidRight customer invoices. 

WRK has seen further acceleration in large scale-execution and de-risking. The next quarter is catalyst rich, with transaction revenue expected to scale, balancing investments.

Mach7 Technologies Ltd (ASX: M7T)

This ASX small-cap is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations.

Last week, it released Q3 FY26 results.

This prompted an unchanged buy recommendation from Morgans, with an updated price target of 44 cents per share. 

The broker noted a lower operating cost base sets the company up well for better operating leverage from FY27.

From yesterday's closing price of 27.5 cents, this indicates an upside potential of approximately 60%. 

The post 3 ASX small-cap stocks every investor should be monitoring appeared first on The Motley Fool Australia.

Let's see what the broker is saying about these speculative stocks.

Immutep Ltd (ASX: IMM)

Immutep is a clinical-stage biopharmaceutical company focused on developing novel LAG3 immunotherapy for cancer and autoimmune disease.

Its shares were sold off this month after its lead drug, Efti, failed the futility analysis in its global Phase 3 trial in non-small cell lung cancer. Bell Potter notes that this "is a bitterly disappointing and surprising outcome considering the strength of the company's prior Phase 1 and Phase 2 lung cancer data."

As a result, it has downgraded its shares to a speculative hold rating with a 7 cents price target (from 65 cents). It said:

We downgrade to a Hold recommendation and $0.07 valuation. We tentatively estimate IMM will end up with ~$60m of cash (4c/sh) following wind-down of the global Phase 3 trial and other Efti development activities, assuming no repayments to Dr Reddy's are necessary.

In addition to cash, IMM retains the earlier-stage IMP761 asset which it will continue to progress for treating autoimmune conditions. The early stage of IMP761's development (no data in patients) leads us to exclude any material contribution from our valuation at this time.

Oneview Healthcare PLC (ASX: ONE)

Another ASX healthcare stock that Bell Potter has been looking at is Oneview.

Its Care Experience Platform (CXP) is a unified set of digital tools in a single bedside solution that connects patients, families, and care teams with services, education, and information during hospital stays.

Bell Potter is positive on the company's growth outlook and has put a speculative buy rating and 45 cents price target on its shares. It said:

There is no change to our earnings estimates but we have reduced our DCF valuation by c.10% to $0.45/sh following FX appreciation and share count adjustments. We assume c.20% annual growth in live endpoints from FY26e-FY28e to drive our FY28e U. EBITDA breakeven expectation.

Given ONE's track record, this is no small feat. In the face of improving thematics and the need for hospitals to utilise efficiency tools to plug the operating impact of nurse shortages, we remain cautious ahead of more consistent performance on conversion and financial performance.

PYC Therapeutics Ltd (ASX: PYC)

Finally, PYC is a clinical-stage biotechnology company that is developing multiple drug candidates for rare inherited diseases.

Bell Potter notes that "following a Type D meeting with the FDA, PYC provided key elements of the Phase 3 trial design for its novel drug candidate, VP-001."

And thanks to its recent $600 million capital raise, PYC has the benefit of >$700 million in cash, with runway into at least 2030 according to the broker. As a result, Bell Potter believes the company is "incredibly well capitalised to execute over the next several years on its clinical development programs without having to come back to investors for additional capital."

For this reason, it has put a speculative buy rating and $2.30 price target on its shares. It said:

There are no changes to our BUY (spec.) recommendation or $2.30/sh valuation. The catalysts most likely to drive enthusiasm include additional RP11 readouts from the Phase 1/2 trial (expected Q4 CY26), clinical data in patients in the PKD trial (CY27 to CY28), and any potential licensing partnerships for the ophthalmology programs.

The post How does Bell Potter rate these ASX healthcare stocks? appeared first on The Motley Fool Australia.

Investors were running for the exit despite some positive results.

For the six months ended 31 December, Pro Medicus reported:

• Revenue up 28.4% to $124.8 million
• Underlying profit before tax up 29.7% to a record $90.7 million
• Underlying EBIT margin expanding to 72.6%
• Interim dividend of 32 cents per share, fully franked. 

On the surface these look like solid results, but investors weren't convinced. 

The ASX healthcare stock has now fallen 42% since the start of 2026. 

Brokers response

Following the brutal sell-off, Bell Potter updated its guidance on the ASX 200 healthcare stock. 

The broker said the outlook statements continue to support expectations of robust growth in the years ahead. 

Despite these positives, the stock has been "priced for perfection" and the 5% miss at the top line was sufficient to trigger a brutal share price reaction.

The earnings miss could not have been more poorly timed in an environment of hyper-sensitivity to the perceived threat to long term earnings posed by the evolution of advanced AI tools. 

In addition the company disclosed that it had been unsuccessful on more than one contract during the period, on the basis of price – not what the market needed on the back of an earnings miss.

Where to from here?

In yesterday's report, Bell Potter reinforced it remains confident on ongoing outlook for revenue and earnings growth. 

However, it significantly reduced its share price target. 

The broker retained its buy recommendation on the basis the current price is an attractive entry point.

The broker now has a price target of $240.00 (previously $320.00) on this ASX 200 healthcare stock. 

This indicates an upside of 86% from yesterday's closing price of $129.00.

Another ASX healthcare stock gets an update

Pro Medicus wasn't the only healthcare stock that endured a tough day of trading yesterday. 

Oneview Healthcare PLC (ASX: ONE) shares dropped more than 7% on Thursday after releasing earnings results.

The company provides patient engagement and clinical workflow technology solutions to healthcare facilities. It serves hospitals and healthcare systems, academic medical centers, and pediatric hospitals.

Following yesterday's results, Bell Potter improved its forecast operating losses (R. EBITDA) over the FY26-FY28 period by 20%/22%/48%. 

The broker retained its speculative buy recommendation and $0.50 price target. 

This indicates an upside of roughly 66%. 

Although the thematics appear to be improving, we remain cautious about the long-term trajectory and therefore moderated our long-term growth assumptions to leave our TP unchanged at $0.50/sh.

The post Broker weighs in on two ASX healthcare shares that crashed yesterday appeared first on The Motley Fool Australia.

After all, just because a stock is trading cheaply does not mean it is a bargain.

But for investors looking to add some high-potential options to their watchlist, here are two with fresh guidance from Bell Potter that could have upside. 

Oneview Healthcare PLC (ASX: ONE)

ONE's Care Experience Platform (CXP) is a unified set of digital tools in a single bedside solution that connects patients, families, and care teams with services, education, and information during hospital stays.

The system is fully automated, integrated, and personalised, which streamlines nursing workflows and positively impacts safe and timely hospital discharges.

Bell Potter has recently raised its valuation on this penny stock thanks to improving cash flows and a key contract win. 

The broker noted that the company reported an operating cash outflow of approximately €1.4m, supported by €3.5m in cash receipts, resulting in a cash balance of €4.6m at the end of the period. 

The result shows a clear improvement both quarter on quarter and year on year, marking the second consecutive quarter of improving cash performance.

Bell Potter also noted the recent contract win as a positive for this ASX penny stock. 

ONE has secured access to a top ten US health system / GPO (name not disclosed) that covers 85 hospitals and 15,000 beds, which is similar in scale to ONE's current onboarded beds. Access to the GPO is via an amendment to Baxter's existing arrangement and enables hospitals to purchase ONE's products.

The broker has raised its price target on Oneview Healthcare to $0.50 (previously $0.25). 

We have rolled forward our DCF valuation and lowered our WACC from 12.5% (after allowing for adjusting our RFR to 4.5%) to 10.1% to reflect improving confidence and cadence of new customer wins.

Based on yesterday's closing price of $0.40, this indicates an upside of 25%. 

Alcidion Group Ltd (ASX: ALC)

Alcidion is a provider of intelligent informatics software for the healthcare sector.

Its share price has risen 25% already in 2025. 

Bell Potter pointed out in a recent report that FY26 contracted revenue is already above FY25. 

FY26 contracted revenue is currently $43.1m (including both sold & renewals), an increase of +$6.8m from $36.3m at the prior quarter and already 6% above FY25 full-year revenue.

Alcidion Group also upgraded its FY26 guidance, lifting EBITDA and operating cash flow from simply "positive" to at least in line with FY25, with potential upside tied to the successful completion of the UHSx contract and the ongoing conversion of new revenue opportunities.

This implies EBITDA >$4.8m and operating cash flow >$5.8m, which Bell Potter views as readily achievable.

Based on this guidance, Bell Potter maintains a buy recommendation on this ASX penny stock along with a price target of $0.17 (previously $0.15). 

Based on yesterday's closing price, this indicates an upside of 36%. 

The post Two ASX penny stocks Bell Potter thinks are worth watching in 2026 appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

DroneShield Ltd (ASX: DRO)

The DroneShield share price is down 3% to $1.17. This may have been driven by profit taking after some strong gains from the counter drone technology company's shares this month. One broker that is likely to see today's pullback as a buying opportunity is Bell Potter. This morning, it reaffirmed its buy rating with an improved price target of $1.50. The broker said: "DroneShield remains our key pick in the Defence sector, with macro tailwinds driving increasing customer demand and the company well capitalised to fund further R&D to maintain its market leading position. We retain our BUY recommendation."

Generation Development Group Ltd (ASX: GDG)

The Generation Development share price is down almost 17% to $4.04. Investors have been selling this financial services company's shares following the release of a market update. The company notes that it delivered a strong performance in the March quarter, with all businesses contributing to growth despite continued market volatility. It seems that the market was expecting an even stronger performance. In addition, today was supposed to be a big day for the company with its shares joining the ASX 200 index to replace De Grey Mining Ltd (ASX: DEG).

Oneview Healthcare PLC (ASX: ONE)

The Oneview Healthcare share price is down 5% to 27.5 cents. This has been driven by the release of the Ireland based healthcare technology company's quarterly update. During the quarter, the company recorded cash receipts of 4.2 million euros but an operating cash outflow of 1.25 million euros. This meant that Oneview ended the period with a cash balance of 12.2 million euros.

PWR Holdings Ltd (ASX: PWH)

The PWR share price is down 7% to $6.21. This has been driven by news that auto part's founder and managing director, Kees Weel, is stepping back from the role temporarily. According to the release, this is so that Weel can seek treatment for an acute medical condition. Chief Technical and Commercial Officer Matthew Bryson will be acting CEO in his absence. Weel said: "While I will remain active in PWR's overall direction, I have advised the Board that concentrating on my recovery is my priority. Matthew Bryson and the Executive Leadership Team have my full support, and I have complete faith that they will be able to deliver on PWR's objectives and the move to PWR's new headquarters, which has successfully commenced."

The post Why DroneShield, Generation Development, Oneview, and PWR shares are falling today appeared first on The Motley Fool Australia.

At the time of writing, Oneview shares are up 2.27% to 45 cents.

Let's take a look at how Oneview performed in the second quarter of 2021.

Oneview share price rises on quarterly report

Earlier today, Oneview released its report for the second quarter ending 30 June 2021.

The company's financial performance was highlighted by a 42% increase on the previous corresponding period (pcp) in net operating cash outflows to €1.24 million ($2 million). This included €1.98 million ($3.18 million) in receipts from customers, a 56% increase on the pcp.

Despite a growing cash outflow, Oneview reported increased administrative and marketing costs for the quarter.

The company also noted a stable balance sheet, with a cash balance of €5.0 million ($8.03 million) as at 30 June 2021.

Oneview reports strong operational highlights

In addition to the company's financial performance for the quarter, Oneview also elaborated on its operational achievements.

In particular, Oneview highlighted the company's 5-year contract extension with its largest customer in Australia, Epworth HealthCare. Oneview also noted its 5-year contract with Northern Health in Melbourne.

Oneview also said it continues to work with its new partner Samsung. Early feedback from their combined market strategy has shown a preference for Cloud Enterprise vs. Cloud Star.

The second quarter of 2021 marked the first quarter of sales and marketing for Oneview's Cloud Enterprise product. The company's management was pleased with the market response and foreshadows a material increases in its sales pipeline.

Snapshot of the Oneview share price

Oneview is an Irish healthcare technology company that provides digital tools for patients and their caregivers.

Facilities systems and services are unified on Oneview's Care Experience Platform with the aim of improving the overall care experience.

The company currently services 63 hospitals, operating in the US, Australia, the Middle East, and Asia.

The Oneview share price has had a stellar year thus far. Shares in the healthcare technology company have surged more than 948% since the start of the year.

The post Here's why the Oneview (ASX:ONE) share price is climbing today appeared first on The Motley Fool Australia.

The healthcare software company's shares have pulled back slightly, still up 6.38% trading at 50 cents at the time of writing.

Let's take a look at what's driving the Oneview share price out of the doldrums to new highs in 2021.

Oneview reveals contract details

Last Friday, Oneview revealed it had signed public healthcare provider Northern Health, its first Cloud Start customer in Australia.

Cloud Start is a fully-managed Samsung tablet solution, enabling virtual care, entertainment, up-to-date patient information and other services.

Under the agreement, Cloud Start will be deployed at the Northern Health, Stage 2 Inpatient Unit Expansion Project, enabling patients to communicate with their clinicians in a COVID-19 safe manner.

In today's announcement, Oneview provided the material terms of the contract with Northern Health.

According to the statement, the agreement will include an initial contract for 126 beds with a term of 5 years.

The implementation will include standard software fee arrangements on a per bed per day basis, where no material conditions need to be satisfied before a customer signs up and becomes legally bound to a contract.

Oneview advised that it does not expect the revenue from this deal to be material in 2021.

The Oneview share price hits ten-bagger status

The Oneview share price has taken investors who bought shares in January to the promised land, surging ~1,010% this year from 4.5 cents to 51 cents at the time of writing.

The healthcare technology company first started making moves on 1 February, when it signed a distribution agreement with Samsung. Under the agreement, Samsung would distribute Oneview's Cloud Start product to healthcare-focused enterprise resellers.

The Oneview share price surged from ~115% from 4.5 cents to 9.5 cents on the day.

The second leg up came about on 12 March, after the company signed an investor awareness agreement with S3 Consortium trading, better known as Next Investors. The company's shares surged 100% from 8 cents to 16 cents on the day of the agreement.

Since then, the company has continued to kick goals, including the attainment of ISO 27001 certification award, the launch of its cloud-based care experience platform, CXP Cloud Enterprise and Friday's first Cloud Start customer signing.

The post Up another 6%, Oneview (ASX:ONE) share price hits 10-bagger status today appeared first on The Motley Fool Australia.

This follows the healthcare technology solutions company's announcement of a new contract.

At the time of writing, Oneview shares are up 4.82% to 43.5 cents.

Let's take a closer look at what Oneview released to the ASX this morning.

What did Oneview announce?

Investors are snapping up Oneview shares after the company added its first Cloud Start customer in Australia.

In today's statement, Oneview advised it has signed a key provider of public healthcare in Melbourne's northern region, Northern Health.

Established in 2000, Northern Health is the major provider of acute, maternity, sub-acute and specialist services in Melbourne's outer northern suburbs. The group comprises four main campuses which are Northern Hospital Epping, Broadmeadows Hospital, Bundoora Centre, and the Craigieburn Centre.

The emergency department treats over 107,000 patients, with over 94,000 patients admitted to hospital each year.

Under the agreement, Oneview's Cloud Start product will be deployed to the Northern Hospital Stage 2 Inpatient Unit Expansion Project. The $162.3 million facility will enable patients to communicate with their clinicians through a digital platform. In turn, users can also connect with family and friends, view entertainment streaming services, and engage in patient education.

The project is expected to go live sometime in the third quarter of 2021. No financial details were given in relation to the revenue generation of the contract.

Oneview share price summary

Founded in 2007, Oneview is an Irish software company that provides interactive healthcare technologies for patients, families and caregivers. The business operates in the United States, Australia, and the Middle East.

Over the last 12 months, Oneview shares have recorded stellar gains, up more than 1,100%. When looking at this year alone, the company's share price is equally impressive, jumping over 860%.

Based on valuation grounds, Oneview presides a market capitalisation of roughly $188 million, with approximately 432 million shares on issue.

The post Why the Oneview (ASX:ONE) share price is climbing today appeared first on The Motley Fool Australia.

While past performance is not an indicator of future performance, there are always valuable lessons to be learnt. As the saying goes, "History doesn't repeat itself, but it often rhymes."

So, without further ado, here are the 5 best performing ASX shares of the year as of today.

Top 5 ASX shares countdown

Renascor Resources Ltd (ASX: RNU)

While all the top 5 best performers are small-cap shares, Renascor Resources is the smallest with a market capitalisation of $152 million. The company operates as a vertically integrated battery anode manufacturer.

It had been a quiet couple of years for Renascor prior to 2021. The South Australian graphite miner's share price had been bouncing between 1 to 2 cents per share. However, with electric vehicles (EVs) booming in popularity, analysts are expecting demand to outstrip supply.

Currently, graphite represents a large portion of the material constituents in lithium-ion batteries. Renascor touts the largest graphite reserve outside of Africa. Which is possibly a contributing factor to the Renascor Resources share price surging 567% year-to-date (YTD).

Sayona Mining Ltd (ASX: SYA)

Sayona Mining is another ASX small-cap share riding the EV wave. Valued at $329 million, this emerging lithium producer is the biggest on our list by market cap.

The initial jump in the company's share price followed a partnership with US-based lithium corporation, Piedmont Lithium Inc (ASX: PLL). That partnership involved Piedmont investing US$12 million into Sayona to become a strategic investor and offtake partner.

President and CEO of Piedmont at the time said, "Piedmont is building a world-class spodumene-to-hydroxide business in North Carolina, and we are now very pleased to be partnering with Sayona to advance a similar business in Quebec."

The Sayona Mining share price has returned 622% since the start of 2021.  

Actinogen Medical Ltd (ASX: ACW)

This Aussie biotechnology company has been busy in 2021. Actinogen has a large addressable market, developing drugs for Alzheimer's disease and the cognitive decline associated with other neurological and metabolic diseases.

A major milestone occurred on 5 February 2021, when the United States Food and Drug Administration (FDA) granted Actinogen's Xanamem drug a Rare Paediatric Disease Designation for the treatment of Fragile X syndrome. Momentum in this ASX share continued as it progressed its clinical development program and appointed a new CEO.

These steps forward have come been greeted with plenty of share price positivity. The Actinogen share price has rewarded shareholders with a 638% return YTD.

Oneview Healthcare PLC (ASX: ONE)

Oneview Healthcare is a cloud-based software provider that offers solutions used in the healthcare sector. These solutions help healthcare workers deliver better and more tailored bedside care. Oneview is our first official 10 bagger on the list. That's right, a 10X return since the start of the year.

This ASX share started the year with a distribution agreement with Samsung SDS America, which is "the enterprise IT solutions provider of Samsung". The deal sent the Oneview share price flying 140% higher in a single day. Since then, the company has entered an investor awareness agreement with S3 Consortium and made a global launch of its CXP Cloud Enterprise software using Microsoft Azure.

Partnering with such iconic brands has undoubtedly drawn investors' attention. And if that hasn't, the 900% share price appreciation YTD should turn a few heads.

Province Resources Ltd (ASX: PRL)

Last, but certainly not least… the best performing ASX share so far this year is Province Resources. This small-cap company is riding another prominent trend of 2021 – hydrogen. Stemming from mineral exploration, Province Resources pivoted towards the booming green hydrogen market early in the year with the acquisition of Ozexco Pty Ltd.

From there, the company entered a memorandum of understanding with global renewable energy leader Total Eren to develop a potential 8-gigawatt green hydrogen project in Australia. By combining wind/solar power and electrolysis, Province Resources hopes to create a green hydrogen production facility in Carnarvon, Western Australia.

The bold, green ambitions have certainly captured the eyes of the market. Province, being the best performing ASX share, has delivered a return of 1,054% in 2021 so far.

The post These 5 ASX shares are delivering the biggest gains in 2021 appeared first on The Motley Fool Australia.

At the close of trade today, the Oneview share price is up 15.2% at 42 cents per share.

Oneview provides patient engagement and clinical workflow technology solutions to healthcare facilities and had a major windfall when it launched its Cloud Care Experience Platform, a platform that allows health systems to quickly adopt technology for engaging patients.

The company provides various inpatient, outpatient and clinical pathway solutions. It generates its revenue in the form of software usage and content revenue, support services, and license fees.

Geographically, Oneview operates in Ireland, the United States, Australia, and the Middle East and North Africa. It generates the majority of its revenue from the USA.

Why is Oneview's Cloud Care Experience Platform useful?

Oneview says that implementing a cloud-based platform for managing patients reduces non-clinical demands on care teams and optimises clinical and operational effectiveness.

The fact that Oneview's platform has had strong support from Microsoft and runs on its platform, Azure, has proven to be a key breakthrough for the company in ensuring an easy rollout into hospitals.

The strong investor response to Oneview's share price has also been due to the product's world-first nature and its release during a time of increased stress on public and private healthcare systems.

Developed with a medical centre

The CXP Cloud Enterprise platform was developed in partnership with NYU Langone Health, a leading academic medical centre in New York, which rapidly rolled out the virtual engagement platform across its facilities during the coronavirus pandemic.

NYU Langone CIO Nader Mherabi said it had arrived at a pivotal time for the healthcare industry.

COVID-19 strained resources and challenged most hospitals to examine how virtual pathways can enhance patient care.

Oneview helped us build an in-patient virtual care platform, which has been instrumental during the pandemic and will continue to be key as we deliver a new level of patient engagement.

Oneview share price snapshot

The Oneview share price has been in the red for 9 of the past 14 days, but today has seen a rapid increase in investment. On the days that the share price has jumped, it's often increased by between 15 and 30%, while declines have been far more moderate.

The Oneview share price is up more than 480% this month and 875% over the past 12 months. 

The post Oneview (ASX:ONE) share price jumps 15% today. Here's why appeared first on The Motley Fool Australia.

CXP Cloud Enterprise launch

Consequently, investors are driving Oneview shares higher after the company's latest update.

According to its release, Oneview advised that it has launched the world's first cloud-based care experience platform, CXP Cloud Enterprise.

Available on Microsoft Azure, the CXP Cloud Enterprise platform offers in-patient care services across health systems such as hospitals. This also includes patient education, meal ordering, patient service requests, apps and digital services, virtual rounding, visitation, and translation services.

Furthermore, Oneview highlighted that its newest platform seeks to reduce non-clinical demands on care teams. This is particularly important given the current digital needs for patients during the pandemic.

The platform was developed in partnership with New York leading academic medical centre, NYU Langone Health. Both parties collaborated on an initial cloud-based version. This partnership saw NYU Langone rollout key capabilities of the platform to over 400 beds in a few weeks. Additionally, this was used to respond to the strain put on healthcare systems, freeing up care teams for other duties.

Today, however, the launch of the CXP Cloud Enterprise platform delivers a full suite of options for patients.

Management commentary

Oneview CEO James Fitter commented:

The cloud-based platform is a key pillar of our growth strategy.

Being the first and only cloud-based care experience solution gives us a strong competitive advantage and means health systems can rapidly implement the capabilities that meet their needs today while providing the agility, scalability and investment protection to grow as their health system changes.

We are excited to know that CXP Cloud Enterprise will help transform the hospital experience for patients, families and care teams.

Microsoft Australia healthcare industry executive Dr. Simon Kos added:

The cloud enablement of Oneview's patient experience platform is a game changer.

It means that health organisations can deploy more quickly, with greater predictability and less specialised resources, all on the trusted Azure cloud. This is a win for patients, clinicians and healthcare organisations that put patient experience and outcomes first.

Oneview share price review

Over the past 12 months, the Oneview share price has increased by over 900%. In particular, this is mostly attributed to year-to-date gains.

Based on the current share price, Oneview presides a market capitalisation of around $141.2 million, with 397.7 million shares outstanding.

The post Why the Oneview (ASX:ONE) share price is rocketing 29% today appeared first on The Motley Fool Australia.

At the time of writing, the healthcare technology solutions company's shares are swapping hands for 35.5 cents, up 14.7%. It's worth noting that at market open, its shares reached an intraday high of 41 cents.

Founded in 2007, Oneview is an Irish software company that provides interactive healthcare technologies for patients, families and caregivers. The business operates in the United States, Australia, and the Middle East.

What's driving the Oneview share price higher?

The Oneview share price is on the move as investors seem pleased with the company's latest update.

According to its release, Oneview advised that it has surpassed a key milestone for the transition to Cloud Enterprise. The company was granted ISO 27001 certification, which is the international standard on best practices to manage information security. In laymen's terms, it proves to clients that their data is safely managed at all times.

Certification Europe, a globally accredited certification body, conducted a thorough independent audit of Oneview's systems, facilities and processes. It found that the company's Information Security Management System (ISMS) protected the confidentiality, integrity, and availability of customer data.

Management commentary

Oneview information security head Richard Eibrand commented:

Information security is especially critical in healthcare and we are very proud of our 13-year unblemished track record protecting the data of our world-class customers.

Cyber security is a top priority for healthcare CIOs and having ISO 27001 certification provides industry-recognised assurance of our good custodianship of highly sensitive healthcare data.

Oneview CEO James Fitter added:

Our journey to ISO certification began in May 2019 as we were developing a complex cloud hosted care management solution for the aged care industry. Our strategic decision to move our hospital solution to the Cloud in 2020 saw us accelerate this initiative in recent months.

The Oneview share price has jumped more than 800% in the past 12 months, with most of these gains coming year-to-date. It's worth noting that the company's shares reached a 52-week high of 48.5 cents on Monday.

The post Here's why the Oneview (ASX:ONE) share price is rocketing 14% appeared first on The Motley Fool Australia.

Here's the data:

Zip Co Ltd (ASX: Z1P)

Zip continued its run as being the most traded ASX share for a sixth week in a row. The buy now pay later (BNPL) provider's shares were attributable to 2.4% of trades on the CommSec platform last week, with 55% coming from buyers. Due to weakness in the tech sector, the Zip share price lost 3.5% of its value during the period.

88 Energy Ltd (ASX: 88E)

A surprise addition to the top five was this energy exploration company's shares ,which were responsible for 1.7% of trades on CommSec. Although its shares surged 36% higher last week, the buying and selling was evenly split. Interestingly, the volume of shares traded was so high it prompted an ASX query. 88Energy advised that it was not aware why its shares were in demand. Though, it notes that it had recently announced the commencement of drilling of the Merlin-1 exploration in Alaska.

Betashares Nasdaq 100 ETF (ASX: NDQ)

This exchange traded fund (ETF) was popular with investors again last week. The NDQ ETF accounted for 1.4% of trades on CommSec over the five days, with 78% coming from the buy side. The US tech-focused ETF lost 1.3% of its value last week.

Afterpay Ltd (ASX: APT)

Afterpay was among the most traded shares on CommSec again last week. It was attributable to 1.4% of trades on the platform, with the buying and selling evenly split at 52% to 48%, respectively. The sellers will have been the happier group, with the Afterpay share price losing 4.5% of its value last week. This was the fourth week in a row of declines.

Oneview Healthcare PLC (ASX: ONE)

Oneview Healthcare shares were another surprise addition to the top five. The healthcare software company's shares were responsible for 1.4% of trades on CommSec, with buyers making up 57% of these trades. Those buyers will have been delighted to see the Oneview Healthcare share price jump 130% over the five days thanks to a new strategic investment.

The post Afterpay and Zip were among the most traded ASX shares last week appeared first on The Motley Fool Australia.

The Oneview Healthcare share price is up a whopping 59% at 38 cents at today's close of trading.

More about Oneview's deal with StocksDigital

In its release to the ASX, Oneview advised it signed an investor awareness agreement with S3 Consortium, trading as StocksDigital, to share research, commentary and investment advice on Oneview.

StocksDigital is an investing and publication company aiming to build a high-performing ASX investment portfolio while sharing research with readers who invest alongside them.

Oneview stated in its release that it needed to take the initiative as there was no coverage of the company's research. It also said it believed media coverage would strengthen its balance sheet.

Boosting the bottom line

Since Oneview's agreement with StocksDigital began on 12 March, its share price has increased by 143.75%.

The agreement is for 18 months. Oneview has allotted StocksDigital 6,250,000 CHESS depositary interests over fully paid ordinary shares rather than pay a $375,000 fee for the company's publicity services.

Additional to its end of the agreement, StocksDigital and other strategic investors in its network invested $1 million into Oneview. In return, 16.6 million CDIs were allotted from Oneview to the participating investors. The company set the offer price at 6 cents apiece – a discount of 18.9% on the volume-weighted average price of CDIs over the prior 5 trading days.

According to Oneview, this capital will be used in the sales and marketing of its new cloud platform.

Oneview Healthcare share price snapshot

The Oneview Healthcare share price reached an intraday high of 42.5 cents, up 80% from yesterday's close.

Year to date, the company's share price is up by a whopping 650%. It's also up 1150% over the last 12 months.

Oneview Healthcare has a market capitalisation of around $93 million, with approximately 424 million shares outstanding.

The post The Oneview Healthcare (ASX:ONE) share price rockets 650% this year appeared first on The Motley Fool Australia.

In early-afternoon trade, the healthcare technology solutions company's shares are up an astonishing 106.2% to 16.5 cents. Almost 100 million shares have swapped hands between investors.

What's the detail in the Oneview agreement?

The Oneview share price rocketed to a new 52-week high as investors appear upbeat about its latest announcement.

According to its release, Oneview advised that it has signed an investor awareness agreement with S3 Consortium trading as StocksDigital. This will see Oneview provided with in-depth research, commentary and investment advice services.

The company stated that this is an important measure taken as no formal research coverage had been relatively conducted. Oneview believes that this will further strengthen the balance sheet and boost investor awareness to build its profile. Indeed, this is a perfectly timed announcement as the company gears up to launch its Oneview Cloud for Enterprise globally. Sales and marketing campaigns are also planned in the near future for the United States and Australia.

The agreement, effective immediately, will run for a period of 18 months. Oneview will pay $375,000 for StocksDigital's services and allocate 6.25 million CHESS depositary interests over fully-paid ordinary shares (CDIs).

In addition to the deal, StocksDigital and investors within its network will invest $1 million into Oneview. In return, the 16,666,666 CDIs will be allotted from Oneview to the participating investors. The offer price will be set at 6 cents apiece. This represents a discount of 18.9% on the volume-weighted average price of CDIs on the last 5 trading days.

The company plans to use the funds to achieve its growth strategy of the new Cloud platform.

About the Oneview share price

The Oneview share price has performed well over the past 12 months, gaining 117%. However, the companies shares have surged to more than 250% year to date, hitting a 52-week high of 19 cents today.

Based on the current share price, Oneview has a market capitalisation of around $65.6 million.

The post Here's why the Oneview (ASX:ONE) share price has exploded 106% higher appeared first on The Motley Fool Australia.

So what is Oneview Healthcare? And (perhaps more importantly) why are Oneview shares worth 140% more today than they were last week?

One-view to a room

Oneview Healthcare is a healthcare company (shocking, I know) that aims to "build technology that fosters holistic, relationship-centred care". The company was founded in 2012 and is listed on the ASX, but incorporated in Ireland (hence the 'plc'). Oneview operates a software-as-a-service (Saas) business model. It sells access to its software platforms, which help healthcare workers deliver better and more tailored bedside care, including to "support COVID-19 response".

Patients and carers can use the software for performing functions like ordering customised meals, video chatting with family or friends, requesting medical attention, accessing entertainment services, and communicating with others for telehealth appointments and similar consultations.

The company's software is used across the United States, Australia, the Middle East and Asia in 55 hospitals spanning 18 different cities. Oneview lists New South Wales Health, Queensland Health, and The Sydney Children's Hospital Network as customers, as well as several large US clients.

Back in August, Oneview reported that the number of beds equipped with its software had grown by 30% year on year in the first half of 2020. It also reported recurring revenue was up 21% to 2.6 million euros. It wasn't all good news though, total revenues fell 15% year on year, largely due to the impact of the pandemic.

Why are Oneview shares racing higher today?

Today's stunning moves in the Oneview share price appear to be the result of a company announcement released to the ASX this morning just before market open. In the release, Oneview told investors the company has signed a "distribution agreement" with Samsung SDS America Inc (Samsung SDSA), which is "the enterprise IT solutions provider of Samsung", to offer a "bundled solution for bedside digital services for patients in the United States".

This agreement will reportedly allow Samsung SDSA to distribute Oneview's Cloud Start product to "healthcare-focused enterprise resellers" beginning this month. Cloud Start runs exclusively on Samsung tablets and was reportedly deployed across four hospitals in New York at the "height of the pandemic" last year. Evidently, the company's technology was well-received.

Oneview CEO James Fitter had this to say on the deal: 

Our move to the cloud accelerates speed to market and opens new possibilities for distribution, making it faster, easier and lower-cost for end-customers to benefit from the digital platform at the bedside. Never has this need been so apparent. Our partnership with Samsung provides a unique opportunity to address new virtual models of care and provide the solution for Samsung SDSA to enhance the value proposition for their reseller network.

Clearly, this agreement has investors pretty excited, judging by today's eye-popping gains in the Oneview share price.

The post ASX stock of the day: Why Oneview Healthcare (ASX:ONE) shares are rocketing 140% today appeared first on The Motley Fool Australia.

Three shares that have caught the eye at the small end of the market are listed below. Here's why they are on the rise today:

The Alacer Gold Corp (ASX: AQG) share price is up over 5% to $2.45. This morning the gold miner provided the market with its latest quarterly activities report. During the third quarter the company achieved production of 26,160 ounces from the Çöpler Gold Mine, bringing its year to date production to 89,233 ounces. As a result, it expects to meet the lower end of its consolidated production guidance for FY 2018. Gold sales during the quarter came to US$37 million, bringing year to date sales to a total of US$124 million.

The Bionomics Ltd (ASX: BNO) share price has bounced 11.5% higher to 19.5 cents. Despite this sizeable gain, the biopharmaceutical company's shares are still down over 60% this week. Bionomics' shares were sold off heavily on Tuesday after the company revealed disappointing results from its phase 2 clinical trial of its BNC210 novel drug candidate in patients with Post Traumatic Stress Disorder (PTSD). The trial did not meet its primary endpoint of a decrease in PTSD symptoms as measured by Clinician-Administered PTSD Scale (CAPS-5) at 12 weeks.

The Swift Networks Group Ltd (ASX: SW1) share price has climbed 5% to 31.5 cents after the telecommunications, content and advertising solutions provider announced that it has executed a 3-year reseller agreement with healthcare software and patient engagement solutions provider Oneview Healthcare (ASX: ONE). The deal will see Swift become an entertainment solutions provider to Oneview customers across the Asia Pacific region and a preferred solutions provider on a global basis. Management believes it will significantly increase its room numbers in the healthcare sector and is targeting 4,000 new screens in the next 36 months.

The post These small cap ASX shares are on the rise on Friday appeared first on The Motley Fool Australia.